Amneal Pharmaceuticals (AMRX) News Today $7.83 -0.04 (-0.51%) Closing price 04:00 PM EasternExtended Trading$7.72 -0.11 (-1.46%) As of 06:55 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 Time Period Hussman Strategic Advisors Inc. Buys 42,000 Shares of Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX)Hussman Strategic Advisors Inc. increased its stake in Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX - Free Report) by 20.0% during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 252,000 shares of the company's stock aFebruary 21 at 6:37 AM | marketbeat.comAmneal Launches Mesalamine and Receives U.S. FDA Approval for LenalidomideFebruary 19 at 12:09 PM | finance.yahoo.comAmneal launches Mesalamine; receives U.S. FDA Lenalidomide approvalFebruary 19 at 12:09 PM | markets.businessinsider.comGeneric Pharmaceuticals Stocks Q3 Teardown: Amneal (NASDAQ:AMRX) Vs The RestFebruary 19 at 7:07 AM | msn.comConvergence Investment Partners LLC Increases Stake in Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX)Convergence Investment Partners LLC raised its stake in shares of Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX - Free Report) by 24.7% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 208,February 19 at 6:19 AM | marketbeat.comAmneal Pharmaceuticals, Inc. (NASDAQ:AMRX) Short Interest Down 18.0% in JanuaryAmneal Pharmaceuticals, Inc. (NASDAQ:AMRX - Get Free Report) saw a large decrease in short interest in January. As of January 31st, there was short interest totalling 2,420,000 shares, a decrease of 18.0% from the January 15th total of 2,950,000 shares. Based on an average daily volume of 1,200,000 shares, the short-interest ratio is currently 2.0 days. Approximately 1.9% of the company's shares are short sold.February 15, 2025 | marketbeat.comEntropy Technologies LP Makes New Investment in Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX)Entropy Technologies LP purchased a new position in Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX - Free Report) during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm purchased 32,757 shares of the company's stock, valued at approximatelFebruary 14, 2025 | marketbeat.comAlthough Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) insiders have sold lately, they have the highest ownership with 51% stakeFebruary 13, 2025 | finance.yahoo.com36,054 Shares in Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) Purchased by Stonebridge Financial Group LLCStonebridge Financial Group LLC acquired a new stake in shares of Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX - Free Report) during the 4th quarter, according to its most recent disclosure with the SEC. The fund acquired 36,054 shares of the company's stock, valued at approximately $286,000. A numberFebruary 12, 2025 | marketbeat.comAmneal Pharmaceuticals, Inc. (NASDAQ:AMRX) Director Gautam Patel Sells 80,000 SharesAmneal Pharmaceuticals, Inc. (NASDAQ:AMRX - Get Free Report) Director Gautam Patel sold 80,000 shares of the company's stock in a transaction that occurred on Monday, February 3rd. The stock was sold at an average price of $8.14, for a total transaction of $651,200.00. Following the sale, the director now directly owns 1,888,886 shares in the company, valued at approximately $15,375,532.04. The trade was a 4.06 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website.February 5, 2025 | marketbeat.comPiper Sandler Sticks to Their Buy Rating for Amneal Pharmaceuticals (AMRX)February 5, 2025 | markets.businessinsider.comAmneal Pharmaceuticals' SWOT analysis: generic drug maker's stock poised for growthFebruary 4, 2025 | msn.comAmneal Pharmaceuticals, Inc. (NASDAQ:AMRX) Receives Average Recommendation of "Moderate Buy" from AnalystsShares of Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX - Get Free Report) have been given a consensus rating of "Moderate Buy" by the five brokerages that are presently covering the company, Marketbeat reports. One research analyst has rated the stock with a hold rating and four have issued a buy raFebruary 3, 2025 | marketbeat.com65,698 Shares in Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) Acquired by China Universal Asset Management Co. Ltd.China Universal Asset Management Co. Ltd. bought a new stake in Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX - Free Report) in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund bought 65,698 shares of the company's stock, valued at apprFebruary 3, 2025 | marketbeat.comAmneal Pharmaceuticals, Inc. (NASDAQ:AMRX) Sees Large Decrease in Short InterestAmneal Pharmaceuticals, Inc. (NASDAQ:AMRX - Get Free Report) saw a significant decline in short interest in the month of January. As of January 15th, there was short interest totalling 3,300,000 shares, a decline of 6.8% from the December 31st total of 3,540,000 shares. Currently, 2.6% of the company's shares are short sold. Based on an average daily volume of 1,050,000 shares, the short-interest ratio is presently 3.1 days.February 1, 2025 | marketbeat.comAmneal to Report Fourth Quarter and Full Year 2024 Results on February 28, 2025January 29, 2025 | businesswire.comBarclays Sticks to Their Buy Rating for Amneal Pharmaceuticals (AMRX)January 27, 2025 | markets.businessinsider.comAmneal Pharmaceuticals (NASDAQ:AMRX) Trading Up 5.2% - Time to Buy?Amneal Pharmaceuticals (NASDAQ:AMRX) Stock Price Up 5.2% - Here's WhyJanuary 23, 2025 | marketbeat.comAmneal Pharmaceuticals Gets FDA Approval for Alzheimer's Treatment and Brain Tumor DrugJanuary 23, 2025 | marketwatch.comAmneal gets FDA approval for memantine/donepezil extended-release capsulesJanuary 23, 2025 | markets.businessinsider.comAmneal gains FDA approval for dementia and oncology drugsJanuary 23, 2025 | msn.comAssenagon Asset Management S.A. Trims Position in Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX)Assenagon Asset Management S.A. cut its stake in Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX - Free Report) by 36.9% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 760,469 shares of the company's stock after selling 444,January 20, 2025 | marketbeat.comAmneal Pharmaceuticals, Inc. (NASDAQ:AMRX) Short Interest UpdateAmneal Pharmaceuticals, Inc. (NASDAQ:AMRX - Get Free Report) was the target of a significant decrease in short interest in the month of December. As of December 31st, there was short interest totalling 3,300,000 shares, a decrease of 6.8% from the December 15th total of 3,540,000 shares. Based on an average daily volume of 1,050,000 shares, the short-interest ratio is presently 3.1 days. Currently, 2.6% of the company's shares are sold short.January 18, 2025 | marketbeat.comAmneal Pharmaceuticals, Inc. (NASDAQ:AMRX) Shares Acquired by Hennessy Advisors Inc.Hennessy Advisors Inc. grew its holdings in Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX - Free Report) by 6.8% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 1,670,600 shares of the company's stock after purchasinJanuary 17, 2025 | marketbeat.comAmneal receives FDA tentative approval for ANDA for rifaximinJanuary 17, 2025 | markets.businessinsider.comAmneal Pharmaceuticals backs prior FY24 EPS view 57c-63c, consensus 61cJanuary 16, 2025 | markets.businessinsider.comAmneal Pharmaceuticals (NASDAQ:AMRX) Releases FY 2024 Earnings GuidanceAmneal Pharmaceuticals (NASDAQ:AMRX) updated its FY 2024 earnings guidance. The company provided EPS guidance of 0.570-0.630 for the period, compared to the consensus estimate of 0.610. The company also issued revenue guidance of $2.7 billionillion-$2.8 billionillion, compared to the consensus estimate of $2.8 billionillion.January 15, 2025 | marketbeat.comAmneal Pharmaceuticals Maintains Transparency with SEC FilingJanuary 15, 2025 | tipranks.comJPMorgan Chase & Co. Purchases 777,568 Shares of Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX)JPMorgan Chase & Co. raised its holdings in Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX - Free Report) by 149.7% during the 3rd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 1,297,094 shares of the company'January 13, 2025 | marketbeat.comInsider Selling: Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) Director Sells 62,590 Shares of StockJanuary 11, 2025 | insidertrades.comGautam Patel Sells 62,590 Shares of Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) StockAmneal Pharmaceuticals, Inc. (NASDAQ:AMRX - Get Free Report) Director Gautam Patel sold 62,590 shares of the business's stock in a transaction that occurred on Wednesday, January 8th. The shares were sold at an average price of $8.01, for a total value of $501,345.90. Following the completion of the sale, the director now owns 1,968,886 shares in the company, valued at $15,770,776.86. The trade was a 3.08 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this link.January 10, 2025 | marketbeat.comAmneal Pharmaceuticals, Inc. (NASDAQ:AMRX) Given Consensus Recommendation of "Moderate Buy" by AnalystsAmneal Pharmaceuticals, Inc. (NASDAQ:AMRX - Get Free Report) has received an average recommendation of "Moderate Buy" from the five research firms that are presently covering the stock, MarketBeat Ratings reports. One research analyst has rated the stock with a hold recommendation and four have isJanuary 9, 2025 | marketbeat.comAmneal Pharmaceuticals, Inc. (NASDAQ:AMRX) Director Sells $139,454.10 in StockJanuary 7, 2025 | insidertrades.comGautam Patel Sells 17,410 Shares of Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) StockAmneal Pharmaceuticals, Inc. (NASDAQ:AMRX - Get Free Report) Director Gautam Patel sold 17,410 shares of the firm's stock in a transaction dated Thursday, January 2nd. The shares were sold at an average price of $8.01, for a total transaction of $139,454.10. Following the completion of the transaction, the director now directly owns 2,031,476 shares in the company, valued at approximately $16,272,122.76. This represents a 0.85 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link.January 6, 2025 | marketbeat.comHere’s Why Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) Is Among the Best Diabetes Stocks to Buy Under $10January 6, 2025 | msn.comAmneal Pharmaceuticals (NASDAQ:AMRX) Stock Quotes, Forecast and News SummaryJanuary 6, 2025 | benzinga.comJane Street Group LLC Has $681,000 Stock Holdings in Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX)Jane Street Group LLC reduced its stake in Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX - Free Report) by 48.0% during the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 81,883 shares of the company's stock after seJanuary 4, 2025 | marketbeat.comGeode Capital Management LLC Has $31.51 Million Position in Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX)Geode Capital Management LLC grew its stake in shares of Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX - Free Report) by 11.1% during the 3rd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 3,786,671 shares ofDecember 26, 2024 | marketbeat.comBarclays PLC Purchases 169,756 Shares of Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX)Barclays PLC boosted its position in shares of Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX - Free Report) by 134.1% in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 296,384 shares of the company's stock afteDecember 26, 2024 | marketbeat.comInvestors Buy High Volume of Amneal Pharmaceuticals Call Options (NASDAQ:AMRX)Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX - Get Free Report) saw some unusual options trading on Monday. Investors bought 2,563 call options on the stock. This represents an increase of approximately 719% compared to the typical daily volume of 313 call options.December 23, 2024 | marketbeat.comAmneal Pharmaceuticals, Inc. (NASDAQ:AMRX) Shares Purchased by State Street CorpState Street Corp grew its stake in shares of Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX - Free Report) by 3.8% in the 3rd quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 3,514,721 shares of the company's stock after buying an additional 127,753December 22, 2024 | marketbeat.comWellington Management Group LLP Buys Shares of 82,596 Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX)Wellington Management Group LLP purchased a new stake in Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX - Free Report) in the third quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor purchased 82,596 shares of the company's stock, valuedDecember 21, 2024 | marketbeat.comAmneal Pharmaceuticals (NASDAQ:AMRX) Rating Lowered to "Buy" at StockNews.comStockNews.com cut shares of Amneal Pharmaceuticals from a "strong-buy" rating to a "buy" rating in a research report on Thursday.December 19, 2024 | marketbeat.comAmneal Pharmaceuticals (NASDAQ:AMRX) Stock Price Up 4.5% - Here's What HappenedAmneal Pharmaceuticals (NASDAQ:AMRX) Trading 4.5% Higher - What's Next?December 17, 2024 | marketbeat.comBNP Paribas Financial Markets Trims Stake in Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX)BNP Paribas Financial Markets lowered its holdings in Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX - Free Report) by 88.1% during the third quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 54,398 shares of the company's stock after sellingDecember 15, 2024 | marketbeat.comAmneal Pharmaceuticals, Inc. (NASDAQ:AMRX) Shares Sold by Jacobs Levy Equity Management Inc.Jacobs Levy Equity Management Inc. lowered its stake in shares of Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX - Free Report) by 66.1% during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 97December 10, 2024 | marketbeat.comCharles Schwab Investment Management Inc. Raises Stock Holdings in Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX)Charles Schwab Investment Management Inc. lifted its holdings in shares of Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX - Free Report) by 16.9% during the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 1,404,883 shDecember 9, 2024 | marketbeat.comAnalysts Have Conflicting Sentiments on These Healthcare Companies: Pacira Pharmaceuticals (PCRX), Amneal Pharmaceuticals (AMRX) and NextCure (NXTC)December 6, 2024 | markets.businessinsider.comWalleye Capital LLC Purchases Shares of 131,667 Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX)Walleye Capital LLC acquired a new position in shares of Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX - Free Report) in the 3rd quarter, according to its most recent disclosure with the SEC. The institutional investor acquired 131,667 shares of the company's stock, valued at approximately $1,095,000.December 6, 2024 | marketbeat.comPolar Asset Management Partners Inc. Purchases 216,400 Shares of Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX)Polar Asset Management Partners Inc. lifted its stake in Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX - Free Report) by 122.5% in the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 393,000 shareDecember 5, 2024 | marketbeat.com Get Amneal Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for AMRX and its competitors with MarketBeat's FREE daily newsletter. Email Address AMRX Media Mentions By Week AMRX Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. AMRX News Sentiment▼1.130.60▲Average Medical News Sentiment AMRX News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. AMRX Articles This Week▼64▲AMRX Articles Average Week Get Amneal Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for AMRX and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies QGEN News Today ROIV News Today ASND News Today RVMD News Today BPMC News Today LEGN News Today AXSM News Today TLX News Today LNTH News Today BBIO News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:AMRX) was last updated on 2/21/2025 by MarketBeat.com Staff From Our PartnersCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredElon “obliterates” Bill Gates?All 10 of the world's biggest money managers follow my work, and the Pentagon, the FBI and Harvard professors ...Altimetry | SponsoredNVDA Crash UpdateAn overseas AI rival sent shockwaves through the U.S. tech market last week... Leaving millions of investor...Chaikin Analytics | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | Sponsored Is Starlink Set For The Largest IPO In History?He turned PayPal from a tiny, off-the-radar startup… to a massive $64 billion giant. Then, he did it again ...Paradigm Press | Sponsored My 2025 AI BlueprintI first recommended Bitcoin at $300 in 2013 … before it went up 33,645%. Now, I am revealing my 2025 AI Blu...Weiss Ratings | SponsoredBetter than Bitcoin – and potentially more profitableThe world is obsessed with Bitcoin again... And for a good reason: It just soared beyond $100,000. Bitcoin ...Brownstone Research | SponsoredAmerica cannot power AIThere’s a fatal flaw at the heart of the AI revolution… With AI continuing to explode in popularity, tech c...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Amneal Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Amneal Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
